Alain Moreau, PhD, is a Professor in both the Department of Stomatology, Faculty of Dentistry and Dept of Biochemistry and Molecular Medicine, Faculty of Medicine, at Université de Montréal, Montréal, Québec, Canada and the Director of Network for Canadian Oral Health Research. He was the Scientific Director, Viscogliosi Laboratory in Molecular Genetics of Musculoskeletal Diseases, Sainte-Justine University Research Center, Montréal, Québec, Canada from 2013-2016. He formerly served as the Vice-chair of the Advisory Committee of the Institute of Musculoskeletal Health and Arthritis (IMHA) at the Canadian Institutes of Health Research (CIHR).
Dr. Moreau's chief interests of study are pediatric scoliosis, osteoarthritis, osteoporosis and Myalgic Encephalomyelitis.
Dr. Moreau is a member of the Working Group which offers their expertise and resources to the ME/CFS Collaborative Research Center at Stanford University.
Notable studies[edit | edit source]
- 2016, IACFSME convention poster - Plasma homocysteine levels and circulating microRNA profiles in patients with ME/CFSStudy info found on page 113
Talks and interviews[edit | edit source]
- June 2015, Presentation by Dr. Alain Moreau to Association Québécoise de l’Encéphalomyélite Myalgique (AQEM) In French
- 12 Aug 2017, Community Symposium on the Molecular Basis of ME/CFS - 2017: Speech title - New research strategies for decoding ME/CFS to improve diagnosis and treatment
- 29 Sep 2018, Deciphering MicroRNAs code in ME/CFS Pathogenesis, given at Second Annual Community Symposium on the Molecular Basis of ME/CFS, sponsored by Open Medicine Foundation - (Video)
- 14 Mar 2019, Role of Stress Activated Circulating MicroRNAs in ME/CFS Pathophysiology given at the International Research Symposium, Geelong, Australia, sponsored by Emerge Australia
Online presence[edit | edit source]
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- "OMF grants $1.2M to Ramp Up Collaborative Research Center at Stanford University". bos.etapestry.com. Retrieved September 12, 2019.
- Alain Moreau, Anita Franco, Sadaallah Bouhanik, Mansour Riazi, Lynda Chadler. (Oct 2016) Plasma homocysteine levels and circulating microRNA profiles in patients with ME/CFS. IACFSME convention poster.
myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.